Business Description
Lushang Freda Pharmaceutical Co Ltd
SIC : 6531
ISIN : CNE000001147
Share Class Description:
SHSE:600223: Class ATotal Employee Number:
3,514Compare
Compare
Traded in other countries / regions
600223.China Index Membership
SSE Composite Index IPO Date
2000-01-13Description
Lushang Freda Pharmaceutical Co Ltd is a Chinese pharmaceutical company controlled by Shandong Lushang Group. Following the divestiture of its real estate operations, the company focuses on pharmaceutical manufacturing and related health businesses. Its main subsidiary, Shandong Freda Pharmaceutical, produces and sells hyaluronic acid and other bioactive ingredients, ophthalmic and orthopedic drug products, and functional skincare and cosmetic products marketed under the Freda brand. The company serves hospitals, pharmacies, distributors, and consumers across China, with a growing export business for its pharmaceutical-grade hyaluronic acid raw materials. Revenue comes from pharmaceutical and cosmetic product sales, raw material supply, and related health services. The company is headquartered in Jinan, Shandong Province, and its shares are listed on the Shanghai Stock Exchange.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 29.91 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.38 | |||||
Interest Coverage | 55.03 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 5.47 | |||||
Beneish M-Score | -2.6 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -32.5 | |||||
3-Year EBITDA Growth Rate | -17.9 | |||||
3-Year EPS without NRI Growth Rate | 41.5 | |||||
3-Year FCF Growth Rate | -39.9 | |||||
3-Year Book Growth Rate | 4.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 18.57 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.87 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.26 | |||||
9-Day RSI | 44.01 | |||||
14-Day RSI | 45.92 | |||||
3-1 Month Momentum % | 4.91 | |||||
6-1 Month Momentum % | -21.13 | |||||
12-1 Month Momentum % | -28.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.55 | |||||
Quick Ratio | 3.99 | |||||
Cash Ratio | 3.18 | |||||
Days Inventory | 102.57 | |||||
Days Sales Outstanding | 44.95 | |||||
Days Payable | 69.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1 | |||||
Dividend Payout Ratio | 0.36 | |||||
3-Year Dividend Growth Rate | -18.3 | |||||
Forward Dividend Yield % | 1 | |||||
5-Year Yield-on-Cost % | 1 | |||||
Shareholder Yield % | 4.3 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 55.19 | |||||
Operating Margin % | 4.83 | |||||
Net Margin % | 4.29 | |||||
EBITDA Margin % | 6.67 | |||||
FCF Margin % | 6.59 | |||||
OCF Margin % | 8.92 | |||||
ROE % | 3.83 | |||||
ROA % | 2.73 | |||||
ROIC % | 6.26 | |||||
3-Year ROIIC % | 0.18 | |||||
ROC (Joel Greenblatt) % | 16.61 | |||||
ROCE % | 5.03 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 35.91 | |||||
Forward PE Ratio | 23.6 | |||||
PE Ratio without NRI | 35.91 | |||||
Shiller PE Ratio | 21.96 | |||||
Price-to-Owner-Earnings | 571 | |||||
PS Ratio | 1.63 | |||||
PB Ratio | 1.36 | |||||
Price-to-Tangible-Book | 1.49 | |||||
Price-to-Free-Cash-Flow | 31.22 | |||||
Price-to-Operating-Cash-Flow | 21.55 | |||||
EV-to-EBIT | 17.99 | |||||
EV-to-EBITDA | 11.3 | |||||
EV-to-Revenue | 0.99 | |||||
EV-to-FCF | 15.06 | |||||
Price-to-GF-Value | 0.81 | |||||
Price-to-Projected-FCF | 0.24 | |||||
Price-to-Median-PS-Value | 1.71 | |||||
Price-to-Graham-Number | 1.51 | |||||
| Price-to-Net-Current-Asset-Value | 2.39 | |||||
| Price-to-Net-Cash | 4.84 | |||||
Earnings Yield (Greenblatt) % | 5.56 | |||||
FCF Yield % | 4.28 | |||||
Forward Rate of Return (Yacktman) % | 1.86 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lushang Freda Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 3,770.66 | ||
| EPS (TTM) (Â¥) | 0.159 | ||
| Beta | 1.0092 | ||
| 3-Year Sharpe Ratio | -0.42 | ||
| 3-Year Sortino Ratio | -0.6 | ||
| Volatility % | 23.76 | ||
| 14-Day RSI | 45.92 | ||
| 14-Day ATR (Â¥) | 0.151978 | ||
| 20-Day SMA (Â¥) | 5.6425 | ||
| 12-1 Month Momentum % | -28.44 | ||
| 52-Week Range (Â¥) | 4.89 - 8.37 | ||
| Shares Outstanding (Mil) | 1,016.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lushang Freda Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lushang Freda Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.057000 Cash Dividend | 2026-07-15 | 5.47 (+3.21%) | ||
| CNY 0.060000 Cash Dividend | 2025-07-24 | 8.40 (-0.47%) | ||
| CNY 0.050000 Cash Dividend | 2024-10-31 | 6.94 (-0.57%) | ||
| 1.25:1 Stock Split | 2006-02-20 | 2.44 (+0.00%) | ||
| 1.3:1 Stock Split | 2000-06-14 | 9.78 (-0.13%) |
Show
Entries
Lushang Freda Pharmaceutical Co Ltd Frequently Asked Questions
What is Lushang Freda Pharmaceutical Co Ltd(SHSE:600223)'s stock price today?
The current price of SHSE:600223 is ¥5.71. The 52 week high of SHSE:600223 is ¥8.37 and 52 week low is ¥4.89.
When is next earnings date of Lushang Freda Pharmaceutical Co Ltd(SHSE:600223)?
The next earnings date of Lushang Freda Pharmaceutical Co Ltd(SHSE:600223) is .
Does Lushang Freda Pharmaceutical Co Ltd(SHSE:600223) pay dividends? If so, how much?
The Dividend Yield %  of Lushang Freda Pharmaceutical Co Ltd(SHSE:600223) is 1% (As of Today), Highest Dividend Payout Ratio of Lushang Freda Pharmaceutical Co Ltd(SHSE:600223) was 1.83. The lowest was 0.16. And the median was 0.46. The  Forward Dividend Yield % of Lushang Freda Pharmaceutical Co Ltd(SHSE:600223) is 1%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers